Stockreport

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission [Financial Post (Toronto, Ontario, Canada)]

Aditxt, Inc.  (ADTX) 
PDF Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their sh [Read more]